Technology
Health
Pharmaceutical

Ocular Therapeutix

$3.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-5.29%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OCUL and other stocks, options, ETFs, and crypto commission-free!

About

Ocular Therapeutix, Inc. Common Stock, also called Ocular Therapeutix, is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Read More Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Employees
167
Headquarters
Bedford, Massachusetts
Founded
2006
Market Cap
172.72M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
436.38K
High Today
$4.22
Low Today
$3.92
Open Price
$4.16
Volume
278.96K
52 Week High
$8.28
52 Week Low
$3.46

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
US
North America

News

Seeking AlphaMar 7

Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q4 2018 Results - Earnings Call Transcript

Ocular Therapeutix (NASDAQ:OCUL) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Antony Mattessich - President and Chief Executive Officer Donald Notman - Chief Financial Officer Scott Corning - Senior Vice President, Commercial Michael Goldstein - Chief Medical Officer Conference Call Participants Adnan Butt - Guggenheim Securities Dan Leone - Raymond James Operator Good afternoon, ladies and gentlemen, thank you for standing by. And welcome to the Ocular Therapeuti...

287
The Motley FoolMar 7

Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript

Ocular Therapeutix Inc (NASDAQ:OCUL) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Ocular Therapeutix Fourth Quarter and Year-end 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. It is n...

17
Seeking AlphaFeb 25

The Story Around Ocular Therapeutix Brightens

This lifted an overhang on the stock and cleared the way for the roll-out of recently approved DEXTENZA. The shares of Ocular Therapeutix jumped 15% in trading Friday as the company entered into a debt facility with favorable terms. "Discomfort is understandable. It's the rudeness that isn't." - N.K. Jemisin, The Fifth Season Ocular Therapeutix (OCUL) had one of its best trading days in quite some time on Friday, rising some 15% on the day. The shares have been challenged like so many "Tier 3" concerns ...

638

Earnings

-$0.64
-$0.55
-$0.46
-$0.37
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.